Marrying cost effectiveness and 'best evidence'

Marrying cost effectiveness and 'best evidence'

John Vernon Cox, DO, FASCO

Jan 13, 2010

Posted ahead of print is an interesting and article by Neubauer, et al : Cost-Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting. Marcus and several of the authors are well known to the clinical practice committee at ASCO. What they report is that the use of pathways in a practice, to harmonize how physicians order lines of therapy for our most common cancer, provides 'best treatment' AND saves money. Though their focus is on community practice - where the far majority of cancer patients are treated - there is no reason to suppose that such efforts would not be generalizable to any practice setting.

Do you use pathways in your practice? Do you see a role to develop common approaches to the major cancers among your colleagues? Can you see your practice sitting down with payers to agree on such approaches?


Do you feel that collaborating with payers to organize the choices that you outline to patients is 'crossing a line'?

I encourage you to read January's JOP --- and look forward to your comments and post on this site.


The ideas and opinions expressed on the ASCO Connection Blogs do not necessarily reflect those of ASCO. None of the information posted on is intended as medical, legal, or business advice, or advice about reimbursement for health care services. The mention of any product, service, company, therapy or physician practice on does not constitute an endorsement of any kind by ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.

Back to Top